Bioanalytic Newsletter No. 2/2009

In this Issue:

 

Dear Reader,

This is the latest edition of the bioanalytic newsletter. With this newsletter we'll inform you about the latest news from ultra-sensitive bioanalytics in drug development, biomarker and diagnostics. We make sure you don't miss any trends or new developments in the future. Have a nice day!

Jessica Rose, Editor-in-Chief, Bioanalytics in Drug Development

 

 

Publication: New technologies in affinity assays to explore biological communication

In this overview, Roper & Guillo highlight several examples from the literature on various types of affinity assays used in different platforms to monitor biological communication of peptides and proteins. read abstract

 

Alzheimer's Disease: Ultra-sensitive Assays available

Based on ultra-sensitive Imperacer® technology, we have set-up extremely sensitive assays for Abeta and TAU targets in a variety of matrices (CSF, plasma, serum, brain homogenate, etc.) Some of these assays quantify even in the sub pg/ml range. read more

 

ICAD 2009 in Vienna

The 2009 International Conference on Alzheimer's Disease (ICAD) will be hosted by Vienna (July 11-16). Catch up with latest bioanalytical technology and visit Chimera Biotec at booth #227

 

Roadshow in the U.S. / On-site demos available

In July we are doing a series of application presentations in the US. If you are interested in an on-site demo of the Imperacer®-assay system, please contact spengler@chimera-biotec.com

 

GLP-certified High Sensitivity CRO-Services

Based on MSD and Imperacer®, we now provide sensitive and ultra-sensitive testing of a wide range of proteins, peptides and biomarkers. CRO Services

 

Frost & Sullivan Award 2008

Best Practices Award2008 European Immunoassay Frost & Sullivan Excellence in Technology Award goes to Imperacer.

For more informations please take a look at the Frost & Sullivan
Press Release
Award Report